Product Description
SAB03 agonizes PD-1, a clinically validated target in rheumatoid arthritis. Current approaches of modulating the target do not address all antigen-reactive T cells. In contrast, Santa Ana’s molecule eliminates and suppresses high-, medium- and low-expressing PD-1 pathogenic T cells. SAB03 has been named as a development candidate, with Phase I testing expected to start next year for a variety of severe inflammatory conditions. (Sourced from: https://www.santaanabio.com/pipeline)
Mechanisms of Action: PD-1 Agonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Santaana bio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Arthritis, Rheumatoid|Inflammatory Bowel Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|